



Gene Set Analysis – Methods and Tools


Antonio Mora, Ph.D.

(Wechat: antoniocmora)

20.12.2018







æ

Learn how to distribute your work using this licence





Contents

- 2.1. What is Gene Set Analysis.
- 2.2. Before starting a Gene Set Analysis.
- 2.3. Gene Set Analysis --ORA
- 2.4. Gene Set Analysis FCS
- 2.5. Multiple testing correction
- 2.6. Gene Set Analysis --Software



2.1. What is Gene Set Analysis?



You may have heard about:

- Pathway (enrichment) Analysis
- Gene Set (enrichment) Analysis
- Functional Enrichment Analysis
- Ontology Analysis
- Knowledge-driven pathway analysis
- And other names...

It is all the same. We are at the end of a research project and we want to find the meaning of the group of biological molecules that we obtained as a result. What is interesting about them? How are they related to each other?



Question: What is interesting about a group of genes?

Simplest method: Google/Baidu/Pubmed your gene and read the papers.

Gene set analysis: Interpreting the query set as pathways or other gene sets.

- Results easier to interpret (familiar processes),
- Mechanistic (suggests possible mechanisms),
- Statistics taking into account.

GNAS DGKZ GUCY1A3 PDE4B PDE4D ATP2A2 ATP2A3 NOS1 CNN1 GST01 NOS3 CNN2 MYLK2 CALD1 ACTA1 MYL2

GNAQ



"Gene Set Analysis" Elements:

A query set: A group of genes that were the result of some experiment

	GNAQ
	GNAS
	DGKZ
	GUCY1A3
	PDE4B
	PDE4D
	ATP2A2
	ATP2A3
→	NOS1
	CNN1
	GST01
	NOS3
	CNN2
	MYLK2
	CALD1
	ACTA1
	MYL2

Reference Databases:

Pathway / Ontology / Gene set DBs.





Statistical Method

Is my group of genes more enriched in one specific gene set than a group of genes randomly chosen?







"Gene Set Analysis" Questions:

1. The ORA / Gene List approach: (e.g. genes with expression change > 2-fold)

Pathway X:

My Gene List:





G2 G7 G7

Or, in general (for the entire database): Are any gene sets (pathways, complexes, diseases, functions) surprisingly enriched with genes from my gene/transcript list?





"Gene Set Analysis" Questions:

2. The FCS / Gene Rank approach: (e.g. entire list, ordered by differential expression)

Pathway X:

My Gene Rank:

G1 G5 G7 G3 G4


Answers the question:
Is Pathway X ranked
"surprisingly high"
when located on my
ranked gene/transcript
list?

Or, in general (for the entire database): Are any gene sets (pathways, complexes, diseases, functions) ranked surprisingly high when located on my ranked gene/transcript list?





Statistical Tests





2.2. Before starting Gene Set Analysis



- Association studies (SNPs, CNVs)

Gene Set Enrichment Analysis:

Input: Query Set and Pathway/GeneSet database.


Example of query set: Differentially expressed genes (up-reg, down-reg, or the entire list).



The Gene / Protein List

- Be careful about gene/protein identifiers.
- Identifiers (IDs) are ideally unique, stable names or numbers that help track database records. For example, your wechat ID, Entrez Gene ID 41232, etc
- Gene and protein information stored in many databases
 - \rightarrow Genes have many IDs
- Records for: Gene, DNA, RNA, Protein
 - Important to recognize the correct record type

We need both the query set and the pathways/gene sets using the same type of identifiers





Common Identifiers

Gene Ensembl ENSG00000139618 Entrez Gene 675

Unigene Hs.34012

RNA transcript GenBank BC026160.1 <u>RefSeq NM_000059</u> Ensembl ENST00000380152

Protein

Ensembl ENSP00000369497 <u>RefSeq</u> NP_000050.2 <u>UniProt</u> BRCA2_HUMAN or A1YBP1_HUMAN IPI IPI00412408.1 EMBL AF309413 PDB 1MIU **Species-specific**

HUGO HGNC BRCA2 MGI MGI:109337 RGD 2219 **ZFIN ZDB-GENE-060510-3** FlyBase CG9097 WormBase WBGene00002299 or ZK1067.1 SGD S00002187 or YDL029W Annotations InterPro IPR015252 OMIM 600185 Pfam **PF09104** Gene Ontology GO:0000724 SNPs rs28897757 **Experimental Platform** Affymetrix 208368_3p_s_at Agilent A_23_P99452 Red =CodeLink GE60169 Recommended Illumina GI_4502450-S




VERSITY

Identifier Mapping

- So many IDs!
 - Software tools recognize only a handful
 - May need to map from your gene list IDs to standard IDs
- Four main uses
 - Searching for a favorite gene name
 - Link to related resources
 - Identifier translation
 - E.g. Proteins to genes, Affy ID to Entrez Gene
 - Merging data from different sources
 - Find equivalent records



ID Mapping Services



if.

	>> Static URL Come back later								
g#	initial alias >> g:GOSt >> g:Sorter >> g:Orth >> g:Cocoa	c#	converted alias >> g:GOSt >> g:Sorter >> g:Orth >> g:Cocoa >> Copy values	name >> g:GOSt >> g:Sorter >> g:Orth >> g:Cocoa >> Copy values	description	namespace			
1	ТР53	1.1	P04637	ТР53	tumor protein p53 [Source:HGNC Symbol;Acc:HGNC:11998]	UNIPROT_GN, ENTREZGENE, VEGA_GENE, DBASS5, DBASS3, HGNC, WIKIGENE			
2	MDM2	2.1	Q00987	MDM2	MDM2 proto-oncogene, E3 ubiquitin protein ligase [Source:HGNC Symbol;Acc:HGNC:6973]	UNIPROT_GN, ENTREZGENE, VEGA_GENE, HGNC, WIKIGENE			
3	207105_S_AT	3.1	000459	PIK3R2	phosphoinositide-3-kinase, regulatory subunit 2 (beta) [Source:HGNC Symbol;Acc:HGNC:8980]	AFFY_HG_U133_PLUS_2, AFFY_HG_FOCUS, AFFY_HG_U133A_2, AFFY_HG_U133A			
4	P60484	4.1	P60484	PTEN	phosphatase and tensin homolog [Source:HGNC Symbol;Acc:HGNC:9588]	UNIPROTSWISSPROT			

- g:Convert
- http://biit.cs.ut.ee/gprofiler/gconvert.cgi

Ensembl Biomart

http://www.ensembl.org

. AFFY HG U95C AFFY_HG_U95D AFFY HG U95E AFFY_HTA_2_0 AFFY HUEX 1 0 ST V2 AFFY_HUGENEFL AFFY HUGENE 1 0 ST V1 AFFY_HUGENE_2_0_ST_V1 AFEY PRIMEVIEW AFEY U133 X3P AGILENT_CGH_44B AGILENT SUREPRINT G3 GE 8X60K AGILENT_SUREPRINT_G3_GE_8X60K_V2 AGILENT_WHOLEGENOME_4X44K_V1 AGILENT WHOLEGENOME 4X44K V2 ARRAYEXPRESS CCDS CCDS ACC CHEMBL CLONE_BASED_ENSEMBL_TRANSCRIPT CLONE BASED VEGA GENE CLONE_BASED_VEGA_TRANSCRIPT CODELINK CODELINK DBASS3 DBASS3_ACC DBASS5 DBASS5_ACC EMBL ENSG ENSP ENST ENS_HS_TRANSCRIPT ENS HS TRANSLATION ENS_LRG_GENE ENS LEG TRANSCRIPT ENTREZGENE ENTREZGENE_ACC ENTREZGENE_TRANS_NAME GO GOSLIM GOA HGNC HGNC ACC HGNC_TRANS_NAME HPA HPA_ACC ILLUMINA_HUMANHT_12_V3 ILLUMINA HUMANHT 12 V4 ILLUMINA_HUMANREF_8_V3 ILLUMINA HUMANWG 6 V1 ILLUMINA_HUMANWG_6_V2 ILLUMINA_HUMANWG_6_V3 MEROPS MIM GENE MIM GENE ACC MIM_MORBID MIM_MORBID_ACC MIRBASE MIRBASE_ACC MIRBASE_TRANS_NAME OTTG OTTP OTTT PDB PHALANX_ONEARRAY PROTEIN_ID PROTEIN ID ACC REFSEQ_MRNA REFSEQ MRNA ACC REFSEQ_MRNA_PREDICTED REFSEQ_MRNA_PREDICTED_ACC



ID Challenges

- Avoid errors: map IDs correctly
 - Beware of 1-to-many mappings
- Gene name ambiguity not a good ID
 - e.g. FLJ92943, LFS1, TRP53, p53
 - Better to use the standard gene symbol: TP53
- Excel error-introduction
 - OCT4 is changed to October-4 (paste as text)
- Problems reaching 100% coverage
 - E.g. due to version issues
 - Use multiple sources to increase coverage


Zeeberg BR et al. Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics BMC Bioinformatics. 2004 Jun 23;5:80




2.3. Gene Set Analysis --ORA



Over-representation analysis (ORA) is the task of identifying the pathways that contain a number of genes from our gene list that would be hard to find by chance alone.




Are the genes in the intersection too many? What do we mean when we say "too many"? 5 out of 10? 7 out of 10? (We must use Statistics!)



<u>Statistical test</u>: Are there more annotations in the gene list than expected by chance alone? (p < 0.05?)



Usually, we do this for all gene sets in the database, and build a table







Statistical (Enrichment) Test:

What do you mean "enriched"? How many genes are "too many"?


The statistical formulation: If we randomly choose "n" genes, how likely is that all the "n" genes will be in a certain pathway?

If it is very unlikely (low probability), we say that the sample genes are over-represented in that pathway.



The most common ORA test is using the "Hypergeometric distribution" (HG).

N = Population



The HG describes the probability (P) of k successes in n draws, without replacement, from a population of size N that contains K successes.

The Statistical Test: Is this more enriched than expected by chance alone? Is it better than P?

N = Number of items in the population

K = Number of items in the population that we call "successes"

n = Number of items in the sample


k = Number of successes in the sample

Question: What is the probability of success P?





Gene List



Adapted from: Canadian Bioinformatics Workshop





Probability of success: P(X=k)

$$P(X=k)=rac{\binom{K}{k}\binom{N-K}{n-k}}{\binom{N}{n}}$$
 .

$$egin{pmatrix} n \ k \end{pmatrix} = rac{n!}{k!\,(n-k)!} \quad ext{for} \ \ 0 \leq k \leq n,$$

$$n! = \prod_{k=1}^{n} k$$

= 1 \cdot 2 \cdot 3 \cdots (n-2) \cdot (n-1) \cdot n
= n(n-1)(n-2) \cdots (2)(1)


$$4! = 4 * 3 * 2 * 1$$



Example: Suppose we randomly select 5 cards without replacement from a deck of cards. What is the probability of getting exactly 2 red cards?

唐州影科大学

GUANGZHOU MEDICAL UNIVERSITY



Example: We have 52 students, 26 tall and 26 small. Suppose we randomly select 5 students from the group. What is the probability of getting exactly 2 tall students?

N = Population = Allstudents = 52K = Population success = All tall students = 26n = Sample = 5k = Sample success = Tall students in the sample = 2 N - K = 26n - k = 3What is the probability of success?

Probability of success: P(X=k)

$$P(X = 2) = \frac{\binom{26}{2}\binom{26}{3}}{\binom{52}{5}}$$

$$P(X=2) = \frac{325 * 2600}{2598960} = 0.3251$$



Example: Suppose we are using a database with 52 genes distributed in two pathways, each having 26 genes. Suppose we found 5 differentially-expressed genes in our experiment. What is the probability of getting exactly 2 genes in pathway A?

N = Population = Allgenes in the database = 52 K = Population success = All genes in pathway A = 26 n = Sample = Our full setof DEG = 5k = Sample success = 2N - K = 26n - k = 3

唐州翳科大学

GUANGZHOU MEDICAL UNIVERSITY

Probability of success: P(X=k)

$$P(X = 2) = \frac{\binom{26}{2}\binom{26}{3}}{\binom{52}{5}}$$

$$P(X=2) = \frac{325 * 2600}{2598960} = 0.3251$$



- But our original question was not the probability of success. The question was if the genes are enriched (over-represented) in that pathway or not.
- We usually accept a threshold of p = 0.05 to decide that.
- Our p = 0.3251 is much higher than that, which means that is easy for those two genes to appear in pathway A just by chance. Therefore, we say that those two genes are not enriched in pathway A.




- ORA tools search for over-representation in a given database of pathways.
- In each case, the sample success is the intersection between our list of genes and one specific pathway (f.ex., if there are 3 genes of our list in pathway B, k=3 for pathway B).
- The tool shows as results the pathways with p smaller than our threshold (usually, 0.05).



The Background

Need to choose "background population" appropriately, e.g., if only portion of the total gene complement is queried (or available for annotation), only use that population as background.




Adapted from: Canadian Bioinformatics Workshop



Should we analyze all genes together? Or separate analyses for up-regulated and down-regulated?

five types of tumours, we illustrate that the separate analysis of up- and downregulated genes could identify more pathways that are really pertinent to phenotypic difference. In conclusion, analysing up- and downregulated genes separately is more powerful than analysing all of the DE genes together.





Should we use all genes in a pathway or gene set?

Some authors filter the gene sets:

Remove gene sets with only a few genes and those with a very large number of genes. Some authors prefer to divide large pathways into sub-pathways:

Low et al. [67] divided the estrogen metabolic pathway into three subpathways involved in androgen synthesis, androgen-to-estrogen conversion and estrogen removal and then found only SNPs within the androgen-to-estrogen conversion pathway were significantly associated with breast and endometrial cancer susceptibilities.



2.4. Gene Set Analysis --FCS




Problems with gene lists

- Threshold for up- and down-regulated genes is arbitrary (f.ex., fold-change > 2, or log-fold-change > 1.5)
- We get different results at different threshold settings.
- Changes in pathway activity can happen not only if we have a few highly differentially expressed genes but also if we have multiple genes more modestly differentially expressed.






Functional Class Scoring (FCS)





How to score a gene set?



Where are the gene-set genes located in the ranked list? Is there distribution random, or is there an enrichment in either end?

Eden E, Lipson D, Yogev S, Yakhini Z. Discovering motifs in ranked lists of DNA sequences. PLoS Comput Biol. 2007 Mar 23;3(3):e39





Pathway Y		
	G1 G5 G7 G3 G4	Is Pathway Y ranked "surprisingly high" when located on my ranked gene/transcript list?

M. Oran Deal


Scoring a gene set using the mean rank:

Gene Set 1	Gene Set 2
Mean Rank = (2+3+4+6+7) / 5 = 4.4	Mean Rank = (4+5+6+7+10) / 5 = 6.4

There are more complex scoring methods, such as: KS, max-mean, and others



GSEA/mHG: Method




Every present gene (thick red vertical bar) gives a positive contribution, Every absent gene (black vertical bar) gives a negative contribution

Warning: the alignment here between bars and plot is a little off

For mHG, ES score = -log P of hypergeometric test at that threshold



GSEA/mHG: Method



1. Maximum (or minimum) ES score is the final **ES score** for the gene set

2. Can define "leading edge subset" as all those genes ranked as least as high as the enriched set.



Going from ES score to p-value

We can compute an empirical p-value using permutations, in the following way:


- 1. Transforming the gene rank into "n" random ranks and then applying the previous procedure in each case. In the end, we will end up with "n" ES values from the random cases.
- 2. Then we will compare our real ES value to all the "n" random ones. Ideally, our ES value should be higher than the random ones, but it is possible to get some cases where it is smaller just by chance. The ratio of times that a random ES is better than the real one, is our p-value. 5 successes of the random ES out of 100 trials would mean a p-value of 0.05.



In statistical terms...

Empirical p-value estimation (for every geneset)


1. Generate null-hypothesis distribution from randomized data





In statistical terms...

Estimate empirical p-value by comparing observed max ES score to null-hypothesis distribution from randomized data (for every gene-set)





2.5. Multiple testing correction



Multiple testing correction

A p<0.05 means that there is still a 5% probability of finding some correlation purely by chance. This is a small number, but if you play it 1000 times, it gets very probable that you will find a positive result just by chance.

Therefore, a *correction for multiple testing* is needed. Some of the methods include *Bonferroni* and *False Discovery Rate (FDR)*.



Simple P-value correction: Bonferroni

* If M = # Tests:

Corrected p-value = M * original p-value

- In other words, we are looking for p<0.05/M. If M is 1000 tests (1000 pathways, f.ex.), now p must be less than 0.00005
- Bonferroni correction is very stringent and can "wash away" real enrichments leading to false negatives



False discovery rate (FDR)

- FDR is the expected **proportion** of the observed enrichments due to random chance.
- Compare to Bonferroni correction which is a bound on the probability that **any one** of the observed enrichments could be due to random chance.
- Typically FDR corrections are calculated using the Benjamini-Hochberg procedure.
- FDR threshold is often called the "q-value"



Benjamini-Hochberg example I

Rank	Category	(Nominal) P-value
1	Transcriptional	0.001
2	regulation	0.002
3	Transcription factor	0.003
4	Initiation of transcription	0.0031
5	Nuclear localization	0.005
	Chromatin modification	
52	•••	0.97
53	Cytoplasmic localization Translation	0.99

Sort P-values of all tests in increasing order



Benjamini-Hochberg example II

Rank	Category	(Nominal) P-value	Adjusted P-value
1	Transcriptional	0.001	$0.001 \times 53/1 = 0.053$
2	regulation	0.002	$0.002 \times 53/2 = 0.053$
3	Transcription factor	0.003	$0.003 \times 53/3 = 0.053$
4	Initiation of transcription	0.0031	$0.0031 \times 53/4 = 0.040$
5	Nuclear localization	0.005	$0.005 \times 53/5 = 0.053$
	Chromatin modification		
52		0.97	0.985 x 53/52 = 1.004
53	Cytoplasmic localization Translation	0.99	0.99 x 53/53 = 0.99

Adjusted P-value is "nominal" P-value times # of tests divided by the rank of the P-value in sorted list Adjusted P-value = P-value X [# of tests] / Rank



Benjamini-Hochberg example III

Rank	Category	(Nominal) P-value	Adjusted P-value	FDR / Q-value
1	Transcriptional	0.001	$0.001 \times 53/1 = 0.053$	0.040
2	regulation	0.002	$0.002 \times 53/2 = 0.053$	0.040
3	Transcription factor	0.003	$0.003 \times 53/3 = 0.053$	0.040
4	Initiation of transcription	0.0031	$0.0031 \times 53/4 = 0.040$	0.040
5	Nuclear localization	0.005	$0.005 \times 53/5 = 0.053$	0.053
	Chromatin modification			
52		0.97	0.985 x 53/52 = 1.004	0.99
53	Cytoplasmic localization Translation	0.99	0.99 x 53/53 = 0.99	0.99

Q-value (or FDR) corresponding to a nominal P-value is the smallest adjusted P-value assigned to P-values with the same or larger ranks.



Benjamini-Hochberg example III

P-value threshold for FDR < 0.05					
Rank	Category	(Nominal) P-value	Adjusted P-value	Q-value	
1	Transcriptional	0.001	$0.001 \times 53/1 = 0.053$	0.040	
2	regulation	0.002	$0.002 \times 53/2 = 0.053$	0.040	
3	Transcription factor	0.003	$0.003 \times 53/3 = 0.053$	0.040	
4	Initiation of transcription	0.0031	$0.0031 \times 53/4 = 0.040$	0.040	
5	Nuclear localization	0.005	$0.005 \times 53/5 = 0.053$	0.053	
	Chromatin modification				
52		0.97	0.985 x 53/52 = 1.004	0.00	
-					
53	Cytoplasmic localization Translation	0.99	0.99 x 53/53 = 0.99	0.99	

Red: non-significant Green: significant at FDR < 0.05

P-value threshold is highest ranking P-value for which corresponding Q-value is below desired significance threshold



2.5. Gene Set Analysis --Software



Where to find software?: Omicstools

(i) Attps://omictools.com/search?q=pathway+analysis	
OMIC TOOLS pathway	analysis Q 💿 ?
SEARCH	
= FILTERS	<
SEARCH FOUND 341 RESULTS	FOR « PATHWAY ANALYSIS »
PLINK Desktop	PLINK A free, open-source whole genome association analysis toolset, designed to perform a range of basic, large-scale analyses in a computationally efficient manner. The focus of PLINK is purely on
PARIS	PARIS / Pathway Analysis by Randomization Incorporating Structure Arrish a data data data data data data data d
SigMod Desktop	SigMod SigMod Market A A A (0) I O discussions Integrates genome-wide association studies (GWAS) results and gene network to identify a strongly interconnected gene module enriched in high association signals. SigMod is formulated as a binary



How to learn to use new software?

- 1. Try to find tutorials (or "vignettes" in R).
- 2. Read the manuals to see all other options that were not covered in the tutorials.
- 3. Ask questions. Don't be afraid to ask (but ask after you tried first).




Submit

Powered by PANTHER

Help



GO



Filter and download (customizable

GO annotations: the model of

biology. Annotations are statements

describing the functions of specific

files <100k lines)

Download ontology

Gene Ontology: the framework for the model of biology. The GO

defines concepts/classes used to

describe gene function, and

What is the Gene Ontology?

An introduction to the Gene
 Ontology









	Homo sapiens (REF)		1	upload 1 (▼ Hiera	rchy	NEW! 🕏	•
GO biological process complete	<u>#</u>	<u>#</u>	<u>expected</u>	Fold Enrichment	<u>+/-</u>	raw P value	<u>FDR</u>
endodermal cell fate specification	<u>6</u>	2	.00	> 100	+	3.79E-07	9.95E-04
→ <u>endodermal cell fate commitment</u>	<u>12</u>	2	.00	> 100	+	1.23E-06	2.42E-03
▶ <u>endodermal cell differentiation</u>	<u>40</u>	2	.01	> 100	+	1.17E-05	1.83E-02
→ <u>endoderm formation</u>	<u>46</u>	2	.01	> 100	+	1.53E-05	2.18E-02
⇔ <u>endoderm development</u>	<u>72</u>	2	.01	> 100	+	3.65E-05	4.42E-02
+formation of primary germ layer	<u>106</u>	3	.02	> 100	+	1.35E-07	7.09E-04
^L → <u>gastrulation</u>	<u>152</u>	<u>3</u>	.02	> 100	+	3.92E-07	8.81E-04
+embryonic morphogenesis	<u>556</u>	<u>3</u>	.08	37.85	+	1.86E-05	2.44E-02
cell fate commitment involved in formation of primary germ layer	<u>26</u>	<u>3</u>	.00	> 100	+	2.35E-09	3.70E-05
^L <u>cell fate commitment</u>	<u>232</u>	<u>3</u>	.03	90.70	+	1.37E-06	2.40E-03
→ <u>cell fate specification</u>	<u>73</u>	2	.01	> 100	+	3.75E-05	4.22E-02
somatic stem cell population maintenance	<u>53</u>	<u>3</u>	.01	> 100	+	1.78E-08	1.40E-04
→ <u>stem cell population maintenance</u>	<u>124</u>	<u>3</u>	.02	> 100	+	2.15E-07	8.44E-04
➡ <u>maintenance of cell number</u>	<u>127</u>	<u>3</u>	.02	> 100	+	2.30E-07	7.25E-04



(i) A https://david.ncifcrf.gov







Gene List 💿 Background 🔵

Step 4: Submit List

Submit List



Annotation Summary Results

						Help and Tool Man
Current Gene Lis	t: List 2			4 DAVID IDs		
Current Backgro	_	10 sap	iens	Check Default	s 🗸	Clear All
Disease (1 selected)					
GAD_DISEASE		4 Ch	art 📃			
GAD_DISEASE_CLASS	100.0%	4 Ch	art			
MIM_DISEASE	25.0%	1 Ch	art 📃			
= Functional_Categ	ories (3 se	lected)				
	25.0%	1 Cha	rt			
	100.0% 4	4 Cha	rt			
	100.0% 4	4 Cha	rt			
UP_SEQ_FEATURE	100.0% 4	4 Cha	rt 📃			
Gene_Ontology (3	selected)					
GOTERM_BP_1	100.0%	4 Ch	art			
GOTERM_BP_2	100.0%	4 Ch	art		_	
GOTERM_BP_3	100.0%	4 Ch	art			
GOTERM_BP_4	100.0%	4 Ch	art		_	
GOTERM_BP_5	100.0%	4 Ch	art 📃		_	
GOTERM_BP_ALL	100.0%	4 Ch	art 📃		_	
GOTERM_BP_DIRECT	100.0%	4 Ch	art		_	
GOTERM_BP_FAT	100.0%	4 Ch	art		_	
GOTERM_CC_1	100.0%	4 Ch	art			
GOTERM_CC_2	100.0%	4 Ch	art			
GOTERM_CC_3	100.0%	4 Ch	art			
GOTERM_CC_4	100.0%	4 Ch	art			
GOTERM_CC_5	100.0%	4 Ch	art			
GOTERM_CC_ALL	100.0%	4 Ch	art			
GOTERM_CC_DIRECT	100.0%	4 Ch	art			
GOTERM_CC_FAT	100.0%	4 Ch	art			
GOTERM_MF_1	100.0%	4 Ch	art			
GOTERM_MF_2	100.0%	4 Ch	art 📃		_	
GOTERM_MF_3	100.0%	4 Ch	art		_	
GOTERM_MF_4	100.0%	4 Ch	art 📃		_	
GOTERM_MF_5	100.0%	4 Ch	art 📃		_	
GOTERM_MF_ALL	100.0%	4 Ch	art			
GOTERM_MF_DIRECT	100.0%	4 Ch	art		_	
	100.0%	4 Ch	art		_	
 ■ General_Annotat ■ Literature (0 select 		ected)				
Main_Accessions						
Pathways (1 select						
KEGG_PATHWAY	100.0%	4 Ch	art		_	
	100.0%	4 Ch	art		_	
Protein_Domains						
🗄 Protein Interacti	ions (0 sele	cted)				

Results for KEGG Pathways



Functional Annotation Clustering

Current Gene List: List_2 Current Background: Homo sapiens 4 DAVID IDs Options Classification Stringency Medium ~ Rerun using options Create Sublist

1 Cluster(s)

<u>Download File</u>

Help and Manual

	Annotation Cluster 1	Enrichment Score: 2.4	G	 Count	P_Value	Benjamini
	GOTERM_BP_DIRECT	somatic stem cell population maintenance	<u>RT</u>	 4	5.5E-8	4.8E-6
	GOTERM_BP_DIRECT	endodermal cell fate specification	<u>RT</u>	 3	2.1E-7	9.1E-6
	KEGG_PATHWAY	Signaling pathways regulating pluripotency of stem cells	<u>RT</u>	 4	8.1E-6	2.4E-5
	GOTERM_BP_DIRECT	regulation of gene expression	<u>RT</u>	 3	1.0E-4	3.0E-3
	GOTERM_MF_DIRECT	transcription factor activity, sequence- specific DNA binding	<u>RT</u>	 4	1.8E-4	5.1E-3
	GOTERM_BP_DIRECT	positive regulation of transcription from RNA polymerase II promoter	<u>RT</u>	 4	2.0E-4	4.3E-3
	GOTERM_MF_DIRECT	<u>transcription regulatory region DNA</u> <u>binding</u>	<u>RT</u>	 3	4.7E-4	6.6E-3
	UP_KEYWORDS	DNA-binding	<u>RT</u>	4	9.9E-4	2.0E-2
	UP_KEYWORDS	Transcription regulation	<u>RT</u>	4	1.5E-3	1.4E-2
	UP_KEYWORDS	Transcription	<u>RT</u>	4	1.6E-3	1.0E-2
	GOTERM_BP_DIRECT	transcription from RNA polymerase II promoter	<u>RT</u>	 3	2.7E-3	4.6E-2
	GOTERM_MF_DIRECT	sequence-specific DNA binding	<u>RT</u>	 3	2.8E-3	2.5E-2
	UP_KEYWORDS	Activator	<u>RT</u>	3	3.0E-3	1.5E-2
	GOTERM_CC_DIRECT	nucleoplasm	<u>RT</u>	4	3.6E-3	3.2E-2
	GOTERM_BP_DIRECT	negative regulation of transcription from RNA polymerase II promoter	<u>RT</u>	 3	5.4E-3	7.4E-2
	UP_KEYWORDS	Developmental protein	<u>RT</u>	 3	6.2E-3	2.4E-2
	UP_KEYWORDS	Isopeptide bond	<u>RT</u>	3	8.7E-3	2.9E-2
	UP_KEYWORDS	Nucleus	<u>RT</u>	 4	1.7E-2	4.7E-2
	UP_KEYWORDS	Ubl conjugation	<u>RT</u>	 3	1.9E-2	4.8E-2
	GOTERM_BP_DIRECT	regulation of transcription, DNA- templated	<u>RT</u>	 3	2.3E-2	2.5E-1
	GOTERM_MF_DIRECT	DNA binding	<u>RT</u>	3	2.8E-2	1.8E-1







Login | Register

13,432,841 lists analyzed 245,575 terms 132 libraries

Analyze

What's New? Libraries

About Help

Find a Gene


Input data

Choose an input file to upload. Either in BED format or a list of genes. For a quantitative set, add a comma and the level of membership of that gene. The membership level is a number between 0.0 and 1.0 to represent a weight for each gene, where the weight of 0.0 will completely discard the gene from the enrichment analysis and the weight of 1.0 is the maximum.

Try an example BED file.

Browse... No file selected.

Or paste in a list of gene symbols optionally followed by a comma and levels of membership. Try two examples: crisp set example, fuzzy set example



Enter a brief description for the list in case you want to share it. (Optional)




Contribute





Enrichr 🌮		Login Register
Transcription Pathways Onto	ologies Disease/Drugs Cell Typ	oes Misc Legacy Crowd
Description No description available (4	4 genes)	目く
KEGG 2016 🛛 🖯	WikiPathways 2016 🛛 🕣	ARCHS4 Kinases Coexp 🛛
Signaling pathways regulating pluripotency of Proteoglycans in cancer_Homo sapiens_hsa(Hippo signaling pathway_Homo sapiens_hsa	Preimplantation Embryo_Homo sapiens_WP Mesodermal Commitment Pathway_Homo s PluriNetWork_Mus musculus_WP1763 Cardiac Progenitor Differentiation_Homo say Endoderm Differentiation_Homo sapiens_WI	ACVR2B_human_kinase_ARCH54_coexpression ROR1_human_kinase_ARCH54_coexpression TAOK3_human_kinase_ARCH54_coexpression HUNK_human_kinase_ARCH54_coexpression PAN3_human_kinase_ARCH54_coexpression
Reactome 2016 Transcriptional regulation of pluripotent ster POU5F1 (OCT4), SOX2, NANOG activate gene POU5F1 (OCT4), SOX2, NANOG repress gene Developmental Biology_Homo sapiens_R-HS Synthesis, secretion, and deacylation of Ghn	BioCarta 2016	HumanCyc 2016
NCI-Nature 2016 Regulation of nuclear beta catenin signaling	Panther 2016 0	BioPlex 2017 © PRTFDC1 PAK2 PAK1 SERPINB1





2

自自自自

TT 10 TS






🔊 Enrichr		Login Register
Transcription Pathways Onto Description No description available (4	logies Disease/Drugs Cell Typ	es Misc Legacy Crowd
	t genes)	
Human Gene Atlas 🛛 🖯	Mouse Gene Atlas 🛛 🖯	ARCHS4 Tissues
PrefrontalCortex	embryonic_stem_line_V26_2_p16	MORULA
CD33+_Myeloid	embryonic_stem_line_Bruce4_p13	ESOPHAGUS (BULK TISSUE)
retina	cornea	AMNIOTIC FLUID
	stomach intestine_large	MIDBRAIN HUMAN EMBRYO
ARCHS4 Cell-lines 0	Allen Brain Atlas up 🛛 🖯	Allen Brain Atlas down 🛛 🖯
BXPC3	Sub paraventricular zone	mantle zone of r3Lim
CFPAC1	Bed nuclei of the stria terminalis, posterior (r6 alar plate
HCC1419	anteroventral periventricular preoptic nucle	intermediate stratum of r6Lim
FADU T84	bed nucleus of the stria terminalis, mediose bed nucleus of the stria terminalis, laterocer	rhombomere 6 rhombomere 7
GTEx Tissue Sample 🛛 🖯	GTEx Tissue Sample 0	Cancer Cell Line 🛛 🕄
Gene Expression GTEX-NPJ8-0011-R7a-SM-2HMJV_brain_male	Gene Expression GTEX-TML8-0326-SM-4GICN_lung_female_40	Encyclopedia KYSE140 OESOPHAGUS
GTEX-X261-0011-R5A-SM-3NMB4_brain_male	GTEX-XUW1-2326-SM-4BOO5_breast_female	TE6_OESOPHAGUS
GTEX-OHPN-0011-R7A-SM-2I5FI_brain_fema	GTEX-R53T-1526-SM-48FEK_breast_female_5	GOS3_CENTRAL_NERVOU5_SYSTEM
GTEX-TSE9-0011-R7A-SM-3DB7P_brain_fema	GTEX-UJHI-0726-SM-3DB92_lung_female_50-	LC1F_LUNG
GTEX-PWO3-0011-R5A-SM-2I5EZ_brain_fema	GTEX-XUJ4-1426-SM-4BONT_lung_female_60	HLC1_LUNG




2 111





문 관리


14 14 16 15 18






• 🖹 🔽 💺 ╁ 🦨 🗳 🕀		3	A	Ø	۲	Enter search te	erm	0	-	H
ntrol Panel										
vork Style Select Dynamic Network 🏶 ClueGO+CluePedia										
y y y	/		0		^					
· · · · · · · · · · · · · · · · · · ·										
ueGO Settings				_						
Ontologies/Pathways 🕎	Evidence 🕐									
Type Name # Date Shape	Code									
GO BiologicalProcess-GOA 15 23.02.2017 Ellipse	All			~						
GO CellularComponent-EBI-Qui 19 13.09.2017 Ellipse	All_Experimental_(E	EXP, IDA, IPI	(IMP,IGI,IEP)							
GO CellularComponent-GOA 18 23.02.2017 Ellipse	All_without_IEA	-								
GO ImmuneSystemProcess-GOA 11 23 02 2017 Ellines	EXP (Inferred from									
GO MolecularFunction-EBI-Quic 48 13.09.2017 Ellipse	IBA (Inferred from IBD (Inferred from									
· · · · · · · · · · · · · · · · · · ·		Diological A	apeur or Descend	e V						
Update Ontologies				2						
Update Ontologies, Pathways & Annotation Files										
REACTOME - Update REACTOME pathways/reactions				\sim						
ClueGO Update										
Retwork Specificity			Detailed	e						
Active Code Use GO Term Fusion () Show only Pathways with pV s			Detailed	_						
Cool Metwork Specificity Good Medun Use GO Term Fusion @ Show only Pathways with pV s Advanced Term/Pathway Selection Options			Detailed	0		3 Network		2 0-0 4	0-0	¥
Advanced Term/Pathways Selection Options			Detailed 0.0	2	Table Pan			■ 0 - 0		
Bood Medium Use GO Term Fusion Image: Comparison of the section of the			Detailed 0.0 Max Level	2 		nel		2 0-0 4		
Network Specificity Good Medun Use GO Term Fusion @ Show only Pathways with pV s Advanced Term/Pathway Selection Options GO Tree Interval 3 Vin Level 8 GO Term/Pathway Selection (#/% Genes)			Detailed 0.0	2 	Table Pan		1	2 0-0 4 €		
Network Specificity Global Use GO Term Fusion @ Show only Pathways with pV s Advanced Term/Pathway Selection Options GO Tree Interval 3			Detailed 0.0 Max Level	2 	Table Pan	nel ■ + ₪ ≡⊙ f(x)		2 0-0 4		
Network Specificity Good Medium Use GO Term Fusion (2) Show only Pathways with pV s Advanced Term/Pathway Selection Options GO Tere Interval 3			Detailed 0.0 Max Level	2 5000 \$ Senes	Table Pan	nel		2 0 - 0 4		
Network Specificity Cool Use 60 Term Fusion Advanced Term/Pathways Selection Options 60 Tree Interval 3	80 🔿 % is		Detailed 0.0 Max Level 4.000 🛧 %C	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		2 0 - 0 4		
Good Medum Use GO Term Fusion Image: Constraint of the second se	00 🔤 % is		Detailed 0.0 Max Level 4.000 🛧 %C	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		C 0-0 Ø		
Oxoli Medum Use 60 Term Fusion Image: Constraint of the state of	60 🔶 % is		Detailed 0.0 Max Level 4.000 🛧 %C	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		2 0-0 4		
Occod Medium Use GO Term Fusion @ Medium Show only Pathways with pV ≤	00 <u>[⊕]</u> % is	Specific	Detailed 0.0 ↓ Max Level ↓ 000 ⊕ %c	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		■ 0-0 ≪		
Book Medium Use GO Term Fusion Image: Comparison of the section options Show only Pathways with pV s Image: Comparison options GO Tree Interval Image: Comparison options GO Term Pathway Selection (#/% Genes) Image: Cluster #1 Cluster #1 Image: Cluster #2 Image: Cluster #2 Image: Cluster #2 Image: Im	60 [\$]% is	Specific	Detailed 0.0 Max Level 4.000 🛧 %C	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		■ 0 - 0 Ø		
Bood Medium Use GO Term Fusion Image: Constraint of the second secon	60 🔶 % is	Specific	Detailed 0.0 ↓ Max Level ↓ 000 ⊕ %c	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		0-0		
Oxoli Medium Use 00 Term Fusion @ Medium Show only Pathways with pV s	00 <u>[⊕</u>]% is	Specific	Detailed 0.0 ↓ Max Level ↓ 000 ⊕ %c	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		■ 0 - 0 Ø		
Block Medium Use GO Term Fusion Image: Constraint of the second seco	60 ♦ % is	Specific	Detailed 0.0 ↓ Max Level ↓ 000 ⊕ %c	2 5000 \$ Senes	Table Pan	nel ■ + ₪ ≡⊙ f(x)		2 0-0 4		
Cooling Medium Use 60 Tem Fusion @ Advanced Tem/Pathways Selection Options GO Tree Interval GO Tree Interval 3 Min Level 8 Contern/Pathways Selection (#/% Genes) Claster #1 S 3 Min #Genes Claster #2 S 3 Min #Genes © OR AND GO Term/Pathway Network Connectivity (Kappa Score) Madum	80 [∳]% is	Specific Han	Detailed 0.0 ↓ Max Level ↓ 000 ⊕ %c	 enes enes 	Table Pan Comparison Comparison	nel ■ + ₪ ≡⊙ f(x)		2 0 - 0 𝔅		\$























Enrichment Map








- Use available gene-set scoring models
 - threshold dependent (e.g. Fisher's) or threshold free (e.g. GSEA)
- Use the network framework to organize gene-sets exploiting their inter-dependencies

http://baderlab.org/Software/EnrichmentMap/





Pathway enrichment analysis software: R / Bioconductor







Final remarks:



- You can always find standalone and web-based applications for pathway analysis, but many tools exist either as scripts or as libraries that you must run.
- Therefore, it is good to learn how to program.
- Currently, the two most popular programming languages in bioinformatics are R and python. R has a suite of software for bioinformatics called "Bioconductor", while python has "bioconda".
- Learn R!





What have we learned today?

What is pathway/gene-set analysis How to perform gene set analysis Two types of gene set analysis (ORA and FCS) What is multiple test correction How to use software for gene set analysis (ORA and FCS)

